News
Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.
GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback